Cardiology Updates Leading Into 2026

Last year’s report highlighted emerging tools – from radial-access interventions to novel lipid therapies – that were sharpening our cardiology toolkit. This year, new clinical trials have converted those innovations into practice-changing evidence. Below we break down the key advances across interventional cardiology, structural heart interventions, electrophysiology, heart failure management, and lipid therapy, heading into 2026.

Interventional Cardiology: Complete Revascularization & Enhanced PCI Tools

• Physiology-guided complete revascularization is now favored in multi-vessel disease: The FIRE trial demonstrated that in elderly MI patients (≥75 years) with multivessel coronary disease, performing PCI on all significant lesions (guided by pressure/flow wires) yields markedly better outcomes than treating only the culprit lesion. At 1 year, the composite of death, MI, stroke or ischemia-driven revascularization occurred in 15.7% of the physiology-guided complete revascularization group versus 21.0% with culprit-only PCI (hazard ratio 0.73, ~27% relative risk reduction). Crucially, this benefit held even among high-bleeding-risk patients, meaning the strategy is broadly applicable. This is a paradigm shift toward making complete revascularization the default, supported by physiology to avoid unnecessary stenting.
• Safer access and calcium modification are enabling more complex PCI: Building on last year’s trends, radial artery access has become standard for PCI whenever possible due to its lower bleeding risk compared to femoral access. Improved calcium modification tools (e.g. intravascular lithotripsy for heavily calcified plaques) and meticulous stent optimization techniques have increased the safety of performing multi-vessel interventions. These advances provide a stronger foundation for pursuing complete revascularization with minimal complications, even in older or high-risk patients.
• Next-generation stents show ultra-low thrombosis rates: Innovation in stent technology continues. Newer drug-eluting stents with ultrathin struts and bioresorbable polymers are demonstrating extremely low rates of stent thrombosis (often ≪1% annually). Such devices maintain efficacy while reducing long-term complications, addressing concerns that earlier-generation DES had with late thrombosis. In short, stents are getting safer and more “forgiving,” which supports aggressive treatment of all significant lesions.
• Intravascular imaging (IVUS/OCT) has become essential, not optional: Multiple studies and real-world data sets in 2025 confirmed that PCI guided by intravascular imaging outperforms angiography-only PCI, especially for complex lesions or multi-vessel cases. Imaging ensures optimal stent expansion and apposition, leading to fewer adverse events. In fact, the latest guidelines have elevated imaging guidance to a Class I recommendation (Level of Evidence A) for complex PCI (e.g., left main disease). Clinical trials have shown that imaging-guided PCI significantly reduces major cardiac events compared to angiographic guidance alone. The take-home message in 2026: use IVUS/OCT routinely to optimize stent results and improve patient outcomes.

Structural Heart Interventions: TAVR Durability & Transcatheter Mitral Breakthroughs

• TAVR holds up long-term in low-risk patients: Five-year outcomes from the Evolut Low Risk trial confirm that transcatheter aortic valve replacement is as durable and effective as surgery in younger, healthier patients. At 5 years, all-cause mortality or disabling stroke was virtually identical between TAVR vs. surgical AVR (15.5% vs 16.4%). Valve performance remained excellent in the TAVR group with no excess of re-interventions or structural degeneration through five years. In other words, TAVR’s early advantages (less invasive, faster recovery) do not come at the cost of mid-term outcomes. This solidifies TAVR as a first-line therapy even in low-surgical-risk severe aortic stenosis, pending individual considerations (anatomy, need for pacemaker, etc.).
• Transcatheter mitral valve replacement (TMVR) achieves surgical-like results in inoperable patients: Massive progress was made in the mitral space. The single-arm ENCIRCLE trial evaluated the Edwards Sapien M3 TMVR device in patients with severe mitral regurgitation who were not surgical candidates. The 1-year results were striking: all-cause mortality 12.9%, heart-failure hospitalization 16.7%, and 95% of surviving patients had none or only mild MR at 1 year. These outcomes far exceeded the performance goal (which was based on ~45% event rates in this population). Essentially, a transcatheter valve delivered mortality and HF hospitalization rates approaching those expected from surgical repair/replacement in operable patients. This indicates TMVR has matured beyond early feasibility – we are now seeing outcomes in non-surgical patients that approach surgical-level efficacy. As TMVR technology and techniques improve, we can expect expanded options for patients with mitral disease who cannot undergo open surgery.
• “Foundation laid, walls going up” for mitral interventions: Last year we noted the groundwork being laid for transcatheter mitral therapies. Now, that groundwork is bearing fruit. Besides TMVR, transcatheter edge-to-edge repair (e.g. MitraClip) continues to evolve for less invasive MR treatment. The success of Sapien M3 in ENCIRCLE underscores that multiple transcatheter approaches (replacement and repair) are converging on surgical-like benefits. The momentum in structural heart disease is clearly moving toward percutaneous solutions for valves that historically required open surgery, with durability and outcomes steadily improving.

Electrophysiology: Pulsed-Field Ablation and Leadless Advances

• Pulsed-field ablation (PFA) is redefining AF ablation with tissue-selective safety: In 2025, PFA emerged as a game-changing ablation modality for atrial fibrillation. Unlike traditional radiofrequency or cryotherapy (which use thermal energy and can damage surrounding structures), PFA uses ultra-rapid electrical pulses that selectively ablate myocardium. Clinical trials like PULSAR reported excellent efficacy – for example, in one study, 94% of pulmonary veins were electrically isolated on the first PFA application, and ~78% of patients with paroxysmal AF remained arrhythmia-free at 1 year. Most importantly, the safety profile is superior: PFA effectively avoids collateral damage such as esophageal injury, phrenic nerve palsy, or pulmonary vein stenosis. In a real-world series of >17,000 PFA cases, there were zero instances of atrio-esophageal fistula or PV stenosis, and overall major complications were ~1% – markedly lower than with thermal ablation. With at least three PFA systems gaining FDA approval in the past year, the technology is rapidly being adopted. Procedures are faster and more operator-friendly as well.

  Bottom line: PFA enables fast, “clean” AF ablation with dramatically improved safety, and is poised to become the standard for atrial fibrillation ablation moving forward.

• Expanding PFA to ventricular arrhythmias: The benefits of pulsed-field energy are now being tested in ventricular tachycardia (VT) ablation, which traditionally is high-risk and challenging. Early first-in-human results (the VCAS study using a FieldForce™ catheter) are promising. In patients with scar-related VT, PFA was able to create deep, transmural lesions in the myocardium and achieved approximately 78% freedom from recurrent VT after ablation. Procedure times were also short. While data are still preliminary, the ability to safely ablate ventricular tissue without damaging surrounding structures (like coronary arteries or the phrenic nerve) could be transformative for treating VT, much as it has been for AF.
• Conduction system pacing outperforms conventional CRT: 2025 cemented the rise of left bundle branch area pacing (LBBAP) as a superior alternative to biventricular pacing for cardiac resynchronization therapy. Results from the large international i-CLAS registry (2,579 patients) showed that CRT achieved via LBBAP leads to better clinical outcomes than traditional BiV lead placement. At ~3 years follow-up, the composite endpoint of all-cause death or first heart-failure hospitalization occurred in only ~22% of LBBAP-CRT patients, versus ~31% in propensity-matched BiV CRT patients (HR ~0.8). The difference was driven mainly by significantly fewer HF hospitalizations with LBBAP (13.6% vs 20.8%). LBBAP also had lower procedural complication rates than BiV (3.5% vs 6.5%), and it achieves more physiologic ventricular activation by engaging the His-Purkinje system. These findings reinforce that pacing directly via the cardiac conduction system (His-bundle or left bundle branch) can provide superior resynchronization, and ongoing trials are likely to make conduction-system pacing a guideline-recommended CRT option.
• Leadless and minimally invasive ICDs reduce hardware complications: In defibrillator therapy, the push for “minimal trauma” continues. An extended 8-year follow-up of the PRAETORIAN trial (PRAETORIAN-XL) confirmed that subcutaneous ICDs (S-ICD), which have no transvenous lead, have significantly fewer long-term complications. Major device-related complications requiring invasive intervention occurred in only 5.7% of S-ICD patients vs 10.2% with conventional transvenous ICDs at 8 years (a nearly 50% relative reduction). Lead-related complications in particular (fractures, infections, etc.) were much lower with S-ICD (2.4% vs 8.3%). S-ICDs were already shown to be noninferior in efficacy; now we see they are superior in safety over the long haul. This aligns with the “think small” philosophy: use the least invasive device that meets the patient’s needs. For patients not requiring pacing, the S-ICD should be strongly considered to avoid the risks of intravascular leads. On the pacing side, leadless pacemakers and leadless CRT systems also continue to advance, further reducing the hardware burden in the body. Overall, electrophysiology is entering a phase of less invasive, more tissue-selective therapies, paralleling what’s happened in interventional cardiology.

Heart Failure: Early SGLT2 Use, Remote Monitoring, and New Therapies

• SGLT2 inhibitors remain foundational, with early initiation in hospitalized patients gaining traction: The class of SGLT2 inhibitors (dapagliflozin, empagliflozin, etc.) is now standard therapy for HFrEF, and new evidence supports starting these medications during acute HF hospitalizations to reap benefits sooner. In the DAPA-ACT HF-TIMI 68 trial, initiating dapagliflozin in hospitalized heart failure patients (both HFrEF and HFpEF) led to a numeric reduction in 2-month risk of cardiovascular death or worsening HF (10.9% on dapagliflozin vs 12.7% on placebo). While this particular trial’s result narrowly missed statistical significance (HR 0.86, p=0.20), the trend mirrored prior smaller studies and meta-analyses suggesting early use is beneficial. Importantly, no safety concerns (e.g., hypotension, renal issues) arose from starting SGLT2 therapy in-hospital. Given the overwhelming chronic benefits and difficulty of initiating therapies after discharge, the practice of starting SGLT2 inhibitors before discharge is becoming more common. Each new dataset reinforces that we should not delay these disease-modifying drugs – even acute patients can tolerate and benefit from them.
• Biggest breakthrough – remote hemodynamic monitoring cuts HF admissions by ~44%: A landmark trial this year, MONITOR-HF, validated that implantable pulmonary artery pressure monitors (CardioMEMS) dramatically improve outcomes in chronic heart failure. This Dutch study showed that using the CardioMEMS sensor to guide therapy led to a 44% relative reduction in HF hospitalization compared to usual care. Patients with the sensor also reported significant improvements in quality of life (KCCQ scores ↑7 points, whereas control patients’ QoL declined). These findings, published in The Lancet and presented at ESC 2023, align with prior US trials (CHAMPION) but provide fresh confidence in a structured European healthcare setting. As a result, there is now broad adoption and reimbursement for remote PA pressure monitoring in patients with recurrent HF admissions. The FDA has approved the CardioMEMS for wider use, and insurance (including Medicare) coverage has expanded. For clinicians, this means we finally have an evidence-based tool to remotely track worsening HF and intervene early – heralding a new era of “preventive” heart failure management. Expect guidelines to incorporate remote monitoring for high-risk HF populations.
• Vericiguat: real-world data confirm benefit in high-risk HFrEF: The soluble guanylate cyclase stimulator vericiguat (approved in 2021 for worsening HFrEF) was highlighted last year as a novel addition to therapy. Now, accumulating real-world evidence and subgroup analyses reinforce its value. In patients recently hospitalized for HF or with persistently severe symptoms, adding vericiguat on top of full guideline-directed therapy consistently yields about a 10% relative risk reduction in the composite of HF hospitalizations or cardiovascular death. While a 10% reduction is modest, these are very sick patients (NYHA III-IV); vericiguat provides a further layer of protection when most other therapies have been applied. Notably, the benefits seem more pronounced in those with very low ejection fraction (<30%) or chronic kidney disease, where other HF drugs might be limited. The takeaway is that vericiguat has secured its niche for “post-decompensation” HFrEF patients to reduce rehospitalization risk. Ensuring such patients are considered for vericiguat (in addition to beta-blockers, ARNI/ACEi, MRA, SGLT2i) is an evidence-backed strategy going into 2026.

Lipid Management and Lipoprotein(a): Aggressive Lowering & New Therapies

• PCSK9 inhibition moves into primary prevention: A headline result in 2025 came from the VESALIUS-CV trial, which tested adding a PCSK9 inhibitor in high-risk patients before a first heart attack or stroke. In this trial, evolocumab was given to patients with risk factors or stable atherosclerosis but no prior MI, on top of statin therapy. LDL cholesterol was driven down to a median of ~45 mg/dL, and major cardiovascular events were reduced by 25% compared to placebo. Notably, the risk of myocardial infarction was reduced by ~36% with PCSK9 inhibition. This is a pivotal finding: it suggests that even for primary prevention, if risk is high enough, aggressively lowering LDL with advanced therapies yields a large benefit. It builds on the notion (mentioned last year) that PCSK9 inhibitors are shifting earlier in the prevention/treatment timeline, not just reserved for refractory hyperlipidemia or post-MI patients. Given their high cost, patient selection is key – but expect guidelines to broaden criteria for PCSK9 inhibitor use in prevention for those with severe hypercholesterolemia or multiple risk factors.
• Inclisiran improves long-term adherence: The siRNA therapy inclisiran (given as two shots a year) was highlighted previously as a tool to ensure sustained LDL lowering. Over the past year, its use in practice has grown, and studies confirm it achieves durable LDL reductions of ~50% with excellent adherence rates since dosing is infrequent. High-risk patients who struggle with daily pills or frequent injections have particularly benefited. Real-world registries show that inclisiran is well-tolerated and effective at maintaining goal LDL levels between the 6-month dosing intervals. This agent is increasingly a part of lipid clinics’ arsenal to achieve guideline LDL targets (<70 or even <55 mg/dL) in ASCVD patients. In short, inclisiran continues to deliver on its promise of “long-acting statin-like” effects, easing the treatment burden for patients.
• Oral PCSK9 inhibitor shows game-changing efficacy: Perhaps the most exciting lipid news is the development of the first oral PCSK9 inhibitor, which could eliminate the need for injections. Merck’s investigational molecule enlici­tide decanoate (MK-0616) reported Phase 3 trial results (the CORALreef program) that exceeded expectations. In a broad population on background statins, a once-daily pill of enlicitide achieved ~56% to 60% reductions in LDL-C at 24 weeks, bringing LDL levels down into the 50 mg/dL range. Equally impressive, it significantly lowered lipoprotein(a) by ~28% as a bonus effect. These numbers are on par with injectable PCSK9 monoclonal antibodies. An oral agent with such efficacy could be transformative by vastly improving accessibility and patient acceptance. Adherence should also improve (no needles). Enlicitide’s trial (CORALreef) met all primary and secondary endpoints, and regulatory submission is underway. If approved in 2026, this could herald a new era of convenient yet powerful LDL lowering – potentially expanding usage to many more patients who need extra lipid reduction beyond statins.
• Lipoprotein(a) can be virtually eliminated by new RNA therapies: Elevated Lp(a) is a major genetic risk factor with no approved treatments – but that is set to change. An siRNA drug targeting LPA (such as SLN360 in development) has shown astounding efficacy in early studies. A single dose of SLN360 in a Phase 1 trial resulted in a median 95–98% reduction in Lp(a) levels at peak effect, and remarkably, participants maintained over an 80% reduction even 5 months later with that single injection. Another agent, an antisense oligonucleotide (Ionis/Novartis’s pelacarsen), in monthly-dose trials also consistently lowers Lp(a) by ~80%. Furthermore, Amgen’s olpasiran (siRNA) in the OCEAN(a)-DOSE trial achieved ~95% Lp(a) drops with quarterly dosing. The text’s reference to “Lipodiceron” achieving 94% at 6 months and 89% at 12 months likely alludes to these kinds of results – essentially, near-complete silencing of Lp(a) production. These therapies are in advanced trials, and at least one is expected to gain approval by 2026–2027 if outcome trials confirm that lowering Lp(a) translates to cardiovascular event reduction. For the first time, we see a path to treat elevated Lp(a) – which could benefit 1 in 5 people (those with high inherited Lp[a]) and further reduce residual cardiovascular risk.

• One-shot gene editing for cholesterol – a glimpse of the future: In a stunning first-in-human study, researchers used a CRISPR-Cas9-based therapy to permanently inactivate the ANGPTL3 gene in the liver – and the initial results are very encouraging. ANGPTL3 is a regulator of lipids; people born without it have very low LDL and triglycerides. In this trial, a single IV infusion of the CRISPR gene-editing treatment (called CTX310) was given to 15 volunteers with refractory hyperlipidemia. Over 60 days of follow-up, LDL cholesterol dropped by nearly 50% and triglycerides by ~55% on average. Importantly, there were no serious adverse events attributable to the therapy, and the effect appeared sustained at the 2-month mark (and ongoing). This is a small Phase 1, but it’s unprecedented – a true “one-and-done” genomic therapy that durably lowers a patient’s cholesterol with a single treatment. If longer follow-up and larger trials confirm safety and lasting efficacy, this could revolutionize preventive cardiology. Imagine treating a genetic cholesterol problem at its source – one infusion to confer lifetime protection. While CRISPR lipid therapy is experimental, 2025 gave us the first proof that it can work in humans. It hints at a future where we cure atherosclerosis risk factors at the DNA level.

  In summary, as we enter 2026, the overarching theme is that cutting-edge tools have matured and their evidence base has caught up. Innovations we discussed a year ago – whether it’s using intravascular imaging, or novel drugs like vericiguat and inclisiran, or new devices – are no longer just promising ideas. They are now proven in clinical trials to improve patient outcomes when fully integrated into practice. Our task at Apex Heart & Vascular is to translate these breakthroughs into everyday care. By embracing physiology-guided PCI, structural interventions, safer EP devices, proactive heart failure monitoring, and aggressive lipid management (down to genetic therapies), we can deliver state-of-the-art cardiovascular care and help our patients lead longer, healthier lives. Here’s to an exciting and beneficial 2026 in cardiology!